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Background: Lymphatic filariasis (LF) caused by Wuchereria bancrofti is present at high prevalence in some parts of
Papua New Guinea. However, there has been no rigorous data-based representative assessment of nationwide
prevalence of LF. The LF programme has been daunted by the scope of the problem, and progress on mass drug
administration (MDA) has been slow and lacking in resources.
Methods: A systematic literature review identified LF surveys in Papua New Guinea between 1980 and 2011.
Results were extracted by location, time period and test used (blood slide, immunochromatographic test (ICT) or
Og4C3 ELISA) and combined by district. Three criteria schemes based on the Global Programme to Eliminate
Lymphatic Filariasis guidelines, with modifications, were developed to classify and prioritize districts by prevalence
level. Results of repeated surveys in the same sites were used to investigate the impact of MDA on LF prevalence
over the time period.
Results: There were 312 distinct survey sites identified in 80 of the 89 districts over the 31-year period. The overall
LF prevalence in the sites tested was estimated at 18.5 to 27.5% by blood slide for microfilariae (Mf), 10.1% to 12.9%
by ICT and 45.4% to 48.8% by Og4C3. Biases in site selection towards areas with LF, and change in type of assay
used, affected the prevalence estimates, but overall decline in prevalence over the time period was observed.
Depending on the criteria used, 34 to 36 districts (population 2.7 to 2.9 million) were classed as high endemic (≥5%
prevalence), 15 to 25 districts (1.7 to 1.9 million) as low endemic (<5%) and 20 to 31 (1.3 to 2.2 million) as non-
endemic. Nine districts (0.7 million) had no information. The strong impact of MDA, especially on microfilaria (Mf)
prevalence, was noted in sites with repeat surveys.
Conclusions: This analytical review of past surveys of LF in Papua New Guinea enables better estimation of the
national burden, identifies gaps in knowledge, quantifies and locates the population at risk, and can be used to
predict the likely impact of MDA and/or vector control. Better targeting of districts by level of prevalence will
strengthen the control programme, facilitate monitoring of the disease trend and increase the likelihood of
reaching the target of LF elimination by 2020.
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Lymphatic filariasis (LF) is a mosquito-transmitted
helminth infection, caused by Wuchereria bancrofti and
transmitted predominantly by Anopheles mosquitoes in
Melanesian countries in the Western Pacific. Papua
New Guinea is often described as having very high
prevalence of LF – perhaps the highest in the world
[1,2]. Sites with very high prevalence have been found in
Papua New Guinea, leading to much groundbreaking
research on the dynamics of transmission, the relationship
between infection and morbidity, and the effect of preven-
tive chemotherapy, also known as mass drug administration
(MDA) [3-7].
Lymphatic filariasis can be transmitted by a wide range
of mosquito genera [8]. The main vectors of LF in Papua
New Guinea are Anopheles mosquitoes (An farauti, An
punctulatus, An koliensis and others) although Culex have
also been found infected [9-12]. Anopheles also transmit
malaria in the majority of the endemic LF districts of
Papua New Guinea. Distribution of LF is known to be very
heterogeneous, being affected by variation in altitude and
possibly by former indoor residual spraying (IRS)
campaigns for malaria, as was observed in the Solomon
Islands and West Papua (formerly Netherlands New
Guinea) [13,14]. Indoor residual spraying with dichlorodi-
phenyltrichloroethane) DDT occurred in the East Sepik
and Madang Provinces of Papua New Guinea from the
1950s to the 1980s [15,16]. Mosquito nets (untreated with
insecticide) have also been shown to be effective in redu-
cing prevalence of LF [17-20]. Recently, malaria endemic
areas have received large scale distributions of insecticide
treated nets (ITN) in 2005–2006 and long lasting insecti-
cidal nets (LLIN) in 2008–2011 [21].
Prevalence of Lymphatic Filariasis in Papua New Guinea
There has been no rigorous data-based representative,
comprehensive and recent assessment of nationwide
prevalence of LF in Papua New Guinea. A summary of
surveys for microfilariae in 46 sites in the New Guinea
mainland and islands between 1912 and 1952 found
prevalence varying from 0% to 71.4%, with a crude average
of 26% [11]. Based on limited survey data from the 1970s
and 1980s, Michael and Bundy [2] put Papua New Guinea
in the 20 to 50% prevalence range using modeling and
prediction. Kazura and Bockarie [1] summarized informa-
tion available to 2003 by district and province, and stated
that prevalence varied from 10% to 92% locally.
A preliminary national estimate of 6% LF prevalence in
Papua New Guinea was obtained based on the LF
Programme mapping prior to the first drug application to
the Pacific Programme to Eliminate Lymphatic Filariasis
(PacELF) [22]. Most of this initial mapping followed the
WHO programme managers’ guidelines for preparing and
implementing national plans to eliminate LF that wereavailable at the time [23], which recommended lot quality
assurance surveys (LQAS) of 250 older schoolchildren or
adults in areas planned to be implementation units (IUs)
where prevalence of LF was not known. However some
other surveys and studies tested as few as 50–100 persons,
as recommended in other WHO documents [24], in order
to classify eligibility of areas for MDA. In both mapping
protocols, a single positive (or more) for Mf or antigenemia
was enough for an area to be classified as endemic for LF.
At the onset of the LF Programme in Papua New Guinea,
planned IUs were defined as provinces, although a signifi-
cant proportion of mapping between 2000 and 2006 was
conducted by district, with usually one site per district
included.
GPELF, PacELF and Papua New Guinea
The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) has the goal of interrupting LF transmission
worldwide by 2020 using a strategy of preventive
chemotherapy – in this case, MDA for at least five years
[25]. In 1999, the Pacific Programme to Eliminate
Lymphatic Filariasis (PacELF), which included Papua
New Guinea, was formed, with MDA starting in Samoa
and Vanuatu shortly thereafter [22]. Most Pacific island
countries and areas have made good progress towards the
elimination goal, but the LF Programme in Papua New
Guinea has suffered from limited resources, challenging ter-
rain and logistical difficulties. Although Papua New Guinea
has been the site of extensive research on LF control, this
has often been done in localized areas and the results not
assessed in a combined manner.
Diagnostic tests for Lymphatic Filariasis
There are currently three recommended tests for
W. bancrofti filariasis: examination of stained blood slides
to detect Mf, the rapid immunochromatographic test
(ICT), and the Og4C3 antigen ELISA assay using serum or
plasma, including elution from dried blood spots. The tests
were described and compared by Gass et al. [26]:
a) Blood slides: thick blood films are made using either
i) 20 ul of fingerprick blood in a circle (as for a
malaria thick blood film), ii) 60 ul of fingerprick
blood in three lines on a slide using a
haemocytometer pipette or a hematocrit tube, or iii)
a larger amount of venous blood (1 to 10 ml) which
is then passed through Millipore filters in the Knott’s
or modified Knott’s methods [27]. Blood films on
slides are not fixed before staining with Giemsa or
similar and examining under x400 with identification
of Mf as described in [28]. Filters, if used, are also
stained and blood is examined on the filter under
×400. For detection of Mf in Papua New Guinea,
blood must be taken at night to maximize the
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some Mf are present in the daytime in heavy
infections, the infection is periodic and both Mf
counts and estimated prevalence will be higher at
night.
b) ICT card test: The rapid immunochromatographic
test detects antigen from the adult worm that is
circulating in the peripheral blood, using a card
format and a coloured line readout. It detects higher
prevalence in the population than Mf tests on blood
slides, since a person may be infected with adult
worms that are not producing Mf. The test uses 100
ul of blood. Originally developed in 1997 [29], the
test is currently available from Binax NOW at
Inverness Medical http://www.binaxnow.com/
filariasis.aspx.
c) Og4C3 antigen ELISA: This is a laboratory-based test
also detecting antigen from the adult worm. The test
uses 50ul of serum or the equivalent eluted from
dried whole blood spots. The test is available from
TropBio http://www.tropbio.com.au.
PNG LF programme
In 2011, Papua New Guinea had 18 provinces, plus the
National Capital District and Autonomous Region of
Bougainville. Two new provinces (Hela and Jiwaka)
were formed in May 2012 by the splitting of Western
Highlands, Enga and Southern Highlands provinces
[30]. According to the National Research Institute report in
2010 [31], there were 89 districts and 231 local level
government areas. The last census was in 2000, when the
estimated population was 5.2 million [31]; the population
in 2012 is estimated by one source to be 6.3 million based
on an annual growth rate of 1.936% [32].
From baseline mapping surveys and using provinces as
the IUs, the Papua New Guinea LF programme initially
concluded that there were only four provinces or equivalent
areas that were completely non-endemic (Eastern
Highlands, Manus, Central and the National Capital
District) and thus did not need MDA [33]. However, the
decision to use the province as the IU became challenging,
as the remaining population of 16 provinces needing to be
covered in each round was huge, and the logistics of getting
adequate coverage (at least 65% of total population)
extremely difficult. At the Regional Programme Managers’
Meeting on Lymphatic Filariasis and other Selected
Neglected Tropical Diseases convened by the WHO
Regional Office for the Western Pacific in 2011 [34], it was
recommended to change the IU from province to district in
order to reduce the size of the target population, to
prioritize the districts and to make the programme rollout
more manageable with a community-based approach.
Research projects have shown that MDA has impacted
LF prevalence dramatically in several provinces includingSouthern Highlands [3], Western [35,36], East Sepik [4,6,7],
Madang [37-39] and New Ireland [40]. These studies have
often been done in limited areas for a few years only, and
in some sites five rounds of MDA did not reduce preva-
lence to below criteria for stopping MDA [7,36,40,41].
However, they provide important information on the
impact of MDA and the combined evidence from these
studies needs to be comprehensively assessed.
In addition to the research studies mentioned above,
one-time province-wide MDAs have also been conducted
in several provinces in conjunction with LLIN distribution.
This was done in 2005 and 2006 in the Autonomous
Region of Bougainville, Oro (Northern), Gulf, New Ireland,
East and West New Britain, East Sepik and Morobe
provinces, but was found not to be a sustainable mechan-
ism for MDA because LLINs are not distributed annually.
Other MDAs were carried out in Milne Bay Province,
which conducted three rounds of MDA in 2005–2007
(including one with LLIN distribution) and two more
rounds in 2010 and 2011. Despite these achievements,
generally the challenges of delivering MDA and monitoring
transmission in Papua New Guinea have been enormous,
resources have been extremely limited and other priorities
including malaria and HIV have predominated.
A new approach is needed to get Papua New Guinea
back on track for elimination by 2020 in line with the global
target [42]. Given the heterogeneity of transmission, it is
likely that large areas without any LF are being targeted
for MDA, while logistical and political issues mean that
some areas with higher prevalence are being neglected.
Therefore, revitalization of the LF Programme and initi-
ation of MDA nationwide in time to meet the 2020 target
is urgently needed, and a thorough and up- to-date review
of LF prevalence level by district may assist in the
prioritization of human and financial resources to over-
come these barriers.
In this study, data were gathered for all locations where
surveys have been done (separately for ICT, Mf and Og4C3
tests). Using this information, areas still to be mapped were
identified, districts with high prevalence were noted for
prioritization and the size of the population at risk was
re-evaluated. District endemicity was classified by three
different criteria and new empirical risk maps for Papua
New Guinea were developed. Changes in prevalence over
time (using three time periods) and the potential impact
and benefits of MDA were also assessed.
Methods
A search of PubMed was done using the terms (‘Papua
New Guinea’ or ‘New Guinea’) and (‘Lymphatic Filariasis’
or ‘Wuchereria bancrofti’ or ‘W.bancrofti’ or ‘filariasis’ or
‘elephantiasis’). Reference lists of published studies were
searched for additional references. Informal James Cook
University survey reports and relevant doctoral theses at
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Guinea and the University of Queensland were retrieved
and searched for survey results and locations. Papua New
Guinea Department of Health reports, PacELF and WHO
meeting reports and records, and MDA drug applications
from 1999 (the start of PacELF) to date were also
examined.
Data on surveys in Papua New Guinea since 1980 were
extracted with locations, numbers tested, numbers positive,
test used, age group, and method of Mf examination, where
available. Research studies testing interventions (mostly
MDA, but some mosquito net projects) were extracted
separately by village and time period where possible.
Occurrence of any MDA or number of MDA rounds in
locations of all surveys was noted, if given or available
from other sources. Coordinates of unknown locations
were obtained from the Geographic Names Server earth-
info.nga.mil/gns/html and/or Global Gazetteer Version 2.2
http://www.fallingrain.com/world. Locations were assigned
to districts using the 2010 district and provincial profiles
from the National Research Institute of Papua New Guinea
[31]. Mapping of prevalence estimates by district was done
using the geographical information system (GIS) shape files
developed by the University of Papua New Guinea Remote
Sensing Centre, available at http://gis.mortxonblacketer.
com.au/upngis/instructions.htm.
Districts were classified as non-endemic, endemic or
unknown by three different criteria schemes and the
results compared. The first criteria scheme was based on
the Global Programme to Eliminate Lymphatic Filariasis
(GPELF) and the second two schemes based on modified
or alternative criteria, which also classified districts into
low endemic and high endemic. The criteria schemes
were as follows:
1. GPELF criteria:
Considering only the most recent mapping survey (target
250 persons tested) by any test in each district:
Zero positives = non endemic
Any positives = endemic
2. GPELF modified criteria:
Considering any test in each district:
Zero positives = non-endemic
If >0% to <5% positive = low endemic
If ≥5% positive = high endemic
Where an unknown district is bordered on all sides by
endemic districts, classify as ‘low endemic’ or ‘highendemic’ based on lowest category found in adjacent
districts.
3. Alternative criteria:
Using data from all surveys, using Mf results if avail-
able, then ICT or Og4C3 results if no Mf tests per-
formed in that district. Considering all positives for the
selected test:
If <1% positive = non-endemic
If ≥1% to <5% positive = low endemic
If ≥5% positive = high endemic
Results
The literature search identified 324 separate survey sites
between 1980 to 2011 that are listed by site and date in
Additional file 1: Table S1. Results of 12 survey sites at the
same location and time that were reported in duplicate
(usually summarized in different ways), were identified and
removed (and noted in Additional file 1: Table S1), leaving
312 separate survey site data points for analysis. The
source of information, location, date (year), type of assay,
the amount of blood tested (for Mf), the time of testing
(for Mf) and the age group tested were noted for each
survey, where available. It was also noted whether any
MDA, and if possible how many MDAs and which drug
used, had been conducted in the locality prior to the
survey.
A survey site represents a distinct named geographic
location tested at a point in time. This may have been a
small number of households in a hamlet that formed
part of a larger group in a village survey. The number of
persons tested per site ranged from 6 to 1666 for Mf
(mean 211 per site), from 1 to 3799 for ICT (mean 290)
and from 9 to 1322 for Og4C3 (mean 209). There were
155 surveys that used Mf, 149 using ICT and 79 using
Og4C3. The total comes to more than the overall num-
ber of survey sites, since some surveys used more than
one test. There was no district that had only Og4C3
surveys; therefore districts were classified by endemicity
using Mf and ICT results only.
Estimates of national prevalence of Lymphatic Filariasis
Combining all the surveys for each assay type gave the
following estimates:
Mf: 27.5%, ICT: 12.9%, Og4C3: 48.8% (Table 1). Since the
results are biased by the differing sample sizes and the fact
that more surveys were done in research sites with high
prevalence of Mf, an alternative estimate was made by
crudely averaging the prevalence in each district (Table 1).
These estimates were:
Mf: 18.5%, ICT: 10.1%, and Og4C3: 45.4%. While these
lower estimates do not eliminate the bias due to surveys
Table 1 Summary percent positive for LF (microfilariae or antigenemia) by district (all surveys conducted 1980–2011)
REGION DISTRICT Pop
2010
est*
No of sites
surveyed Mf
%
pos
Mf
N
tested
Mf
No of sites
surveyed ICT
%
pos
ICT
N
tested
ICT
No of sites
surveyed
Og4C3
% pos
Og4C3
N tested
Og4C3
Endemic
GPELF
Criteria
Endemic mod
GPELF Criteria
Endemic
Alt Criteria
Bougainville
autonomous
region
Central
Bougainville
48145 3 4.3 694 1 0 415 Yes Low Low
North
Bougainville
84825 3 20.2 322 1 12.8 218 3 64.7 331 Yes High High
South
Bougainville
70310 1 5.0 280 Yes High High
Central Abau 48177 1 0 250 No No No
Goilala 34327 1 0 250 No No No
Kairuku-Hiri 98900 4 0 1062 No No No
Rigo 49555 4 0 768 No No No
Chimbu (Simbu) Chuave 43545 1 0 250 No No No
Gumine 43426 1 0.8 250 Yes Low No
Karimui-
Nomane
43859 ? ? ?
Kerowagi 66209 1 2.4 250 Yes Low Low
Kundiawa-
Gembogl
70560 1 0 250 No No No
Sina Sina-
Yonggomugl
45888 1 0 250 No No No
East New Britain Gazelle 114921 2 12.8 500 Yes High High
Kokopo 74687 2 22.6 115 3 28.8 697 2 62.8 419 Yes High High
Pomio 57558 3 11.1 262 3 25.3 403 3 45.1 366 Yes High High
Rabaul 34624 24.4 250 Yes High High
East Sepik Ambunti-
Dreikikir
68864 48 33.8 19235 13 68.0 3488 Yes High High
Angoram 85521 1 1.1 90 Yes Low Low
Maprik 71859 1 1.0 200 Yes Low Low
Wewak 79515 3 25.7 1086 Yes High High
Wosera Gawi 61419 1 1.0 200 Yes Low Low
Yangoro
Saussia
59432 1 4.1 121 Yes Low Low
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Table 1 Summary percent positive for LF (microfilariae or antigenemia) by district (all surveys conducted 1980–2011) (Continued)
Eastern Highlands Daulo 38487 1 0 250 No No No
Goroka 89342 1 0 250 No No No
Henganofi 69326 1 0 250 No No No
Kainantu 114081 1 0 250 No No No
Lufa 57019 1 0 250 No No No
Obura-
Wonenara
36905 2 0 750 No No No
Okapa 77124 1 0 250 No No No
Unggai-
Benna
55947 2 0 750 No No No
Enga Kandep 63086 ? ? ?
Kompiam 59003 1 0 186 No No No
Lagaip-
Porgera
121117 1 0 113 No No No
Wabag 78192 1 0.98 205 Yes Low No
Wapen-
amanda
71267 ? ? ?
Gulf Kerema 84665 2 19.3 688 2 30.2 716 1 64.9 222 Yes High High
Kikori 53515 1 2.8 250 Yes Low Low
Madang Bogia 74537 1 1.0 100 Yes Low Low
Madang 113159 1 32.3 96 Yes High High
Middle Ramu 75548 1 41.5 106 1 13.0 92 3 35.5 262 Yes High High
Rai Coast 73486 1 10.3 68 Yes High High
Sumkar 87522 4 23.9 2032 3 49.5 1690 Yes High High
Usino-Bundi 52314 4 7.8 2510 4 31.2 2488 Yes High High
Manus Manus 56083 1 0 250 No No No
Milne Bay Alotau 95551 8 21.1 479 6 32.6 988 5 57.5 1101 Yes High High
Esa’ala 54588 3 55.4 1250 Yes High High
Kiriwina-
Goodenough
63961 3 20.0 1076 Yes High High
Samarai-
Murua
55246 4 40.0 400 6 7.4 2187 7 24.0 1199 Yes High High
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Table 1 Summary percent positive for LF (microfilariae or antigenemia) by district (all surveys conducted 1980–2011) (Continued)
Morobe Bulolo 101795 1 30.2 149 Yes High High
Finschafen 59690 1 30.0 250 Yes High High
Huon 78454 1 29.7 128 Yes High High
Kabwum 55204 1 30.4 115 Yes High High
Lae 157082 1 30.1 226 Yes High High
Markham 65071 1 13.2 250 Yes High High
Menyamya 90347 1 6.0 100 Yes High High
Nawae 46183 1 28.0 250 Yes High High
Tewae-Siassi 57107 1 2.7 150 Yes Low Low
National Capital
District
Moresby
North East
120664** 2 6.2 341 Yes High High
Moresby
North West
120664 ? ? ?
Moresby
South
120666 6 1.4 1019 Yes Low Low
New Ireland Kavieng 71099 4 15.5 380 2 12.5 767 4 55.5 418 Yes High High
Namanatai 86416 16 20.0 2029 6 9.8 11884 6 44.9 1307 Yes High High
Northern (Oro) Ijivitari 88727 1 0 402 2 2.0 702 1 3.1 416 Yes Low No
Sohe 84961 1 0 462 2 0.9 750 1 1.0 484 Yes Low No
Southern
Highlands
Ialibu-Pangia 76654 1 0 250 No No No
Imbonggu 90667 1 1.9 213 Yes Low Low
Kagua-Erave 82261 ? ? ?
Komo-
Margarima
96818 ? ? ?
Koroba-
Kopiago
104986 ? ? ?
Mendi-
Munihu
145483 1 0.8 250 Yes Low No
Nipa-Kutubu 148640 7 39.8 771 1 51.9 181 Yes High High
Tari-Pori 78783 ? ? ?
West New Britain Kandrian-
Gloucester
79356 3 2.5 355 4 19.5 523 4 55.4 417 Yes High Low
Talasea 183437 2 2.9 377 1 6.1 412 2 22.9 455 Yes High Low
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Table 1 Summary percent positive for LF (microfilariae or antigenemia) by district (all surveys conducted 1980–2011) (Continued)
West Sepik
(Sandaun)
Aitape-Lumi 67670 ? Low ?
Nuku 58339 1 3.7 136 Yes Low Low
Telefomin 45112 1 10.9 193 Yes High High
Vanimo-
Green River
64335 1 22.0 250 Yes High High
Western (Fly) Middle Fly 77277 3 41.4 1138 2 69.4 674 15 53.0 2374 Yes High High
North Fly 70443 35 25.8 4826 1 57.0 676 Yes High High
South Fly 64388 2 0.4 500 Yes Low No
Western
Highlands
Anglimp-
South Wahgi
123618 1 0.4 250 Yes Low No
Dei 63706 1 2.4 250 Yes Low Low
Jimi 47856 1 0 234 No No No
Mount
Hagen
111305 2 0.9 450 Yes Low No
Mul-Baiyer 72563 1 0.8 250 Yes Low No
North Wahgi 66363 1 0.8 250 Yes Low No
Tambul-
Nebilyer
77859 1 0.8 250 Yes Low No
Grand Total 6829240 167 27.5 37425 148 12.9 43264 79 48.8 16221
Crude average of
sites
18.5 10.1 45.4
* obtained from source [31] with adjustment of 2000 census district figures by province- specific growth rates 1980–2000.
** population of National Capital District equally divided between three districts.
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they represent the best estimates in the absence of a
national survey with representative sampling.
Comparison between diagnostic tests
When used on the same population and time point, Mf
tests are expected to give lower percent prevalence
estimates than serological tests that detect adult worm
antigen (ICT or Og4C3) [26]. However, in Table 1 it
can be seen that lower prevalence by Mf is not always
observed for the summarized district data or overall
(see previous paragraph), as a result of combining
surveys done in different locations and times. Detailed
comparison of diagnostic tests is beyond the scope of
this paper and will be reported separately, but it can be
seen in Additional file 1: Table S1 that the expected
relationships between tests are observed when considering
only those sites that used more than one test at the same
survey. Prevalence estimated by Mf was always lower than
ICT prevalence (19 comparisons) and Mf prevalence only
exceeded Og4C3 prevalence for one survey in 1994 (total
of 47 comparisons).
Surveys classified by time period
The number of sites surveyed by year is shown in Figure 1
while the number of persons tested per year is shown in
Figure 2. The first survey identified was in 1983. Three
years (1989, 2007 and 2009) had no surveys by any test. All
surveys prior to 1990 detected Mf in blood, while the
majority after 2000 used ICT. Og4C3 tests started in 1990
while the first ICT tests were done in 1996.
Surveys were divided into approximately three equal
time periods: 1983–1992 (10 years), 1993–2002 (10 years)
and 2003–2011 (9 years), to investigate changes over
time. There was a decline in the percentage positive in0
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Figure 1 Number of individual survey sites by year, classified by assaMf and Og4C3 tests over the three periods (Table 2),
but no obvious decline in ICT percentage positive in the
latter two time periods.
Overall classification of districts and mapping
Data were summarized by district for all surveys in each
district, by test, and are shown in Table 1. Using the three
sets of criteria described in the methods section, numbers
of districts in each category are shown in Table 3.
Figures 3a, 3b and 3c show the classification of endemicity
by district, shaded according to the three criteria schemes
described above.
Overall the picture is similar for most districts by any
criteria scheme, in that lowland and coastal districts were
more likely to be endemic than inland highland districts. A
major distinction between the schemes is that criteria
scheme 1 gives only a ‘yes or no’ classification of prevalence,
whereas both criteria schemes 2 and 3 divide prevalence
into 3 levels – non-endemic, low and high. Criteria
schemes 1 (GPELF) and 2 (GPELF modified) classify many
more districts as endemic compared to the criteria scheme
3 (alternative), mainly because in the first two schemes, a
single positive by any test classifies a district as endemic
(regardless of sample size). In the alternative criteria
scheme 3, ≥1% of tested persons must be positive (in Mf
surveys if available; if not then ICT, with all surveys over
time combined) in order for a district to be classified as
endemic.
No surveys have been conducted to date in nine districts
(of 89 total), in the following provinces: Chimbu (one
district), Enga (two districts), NCD (one district), Southern
Highlands (four districts), and West Sepik (one district).
The unknown district in West Sepik (Aitape Lumi) was
surrounded by endemic districts, and therefore classified
under criteria scheme 2 as low endemic based on level ofMf
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districts were each adjacent to both non-endemic and
endemic districts and therefore have not been classified.Impact of MDA on prevalence of Lymphatic Filariasis
It was known whether or not MDA had occurred prior to
the survey in all except one case (see Additional file 1:
Table S1). The majority of the surveys occurred prior to
any MDA. The number of MDAs at each site was also
obtained from the available studies and reports.
In order to examine whether the decline in percentage
positivity over time, which is apparent in Table 2 as noted
above, was due to MDA or other interventions, sites with
repeated surveys were categorized into groups having had
0, 1, 2, 3, 4 or > =5 MDAs prior to the survey (Table 4).
The location, serological test used and MDA drug type and
frequency are shown with the LF prevalence results from
these sites in Table 4 for the appropriate time periods. The
impact on prevalence of annual or twice a year MDA is
shown graphically for Mf assays in Figure 4 and for ICT
and Og4C3 assays in Figure 5. The impact on Mf preva-
lence was found to be very rapid and large (Figure 4)Table 2 Summary of survey results by three time periods
Mf ICT Og4C3
No
sites
No
persons
%
pos
No
sites
No
persons
%
pos
No
sites
No
persons
%
pos
1983–
1992
50 6539 30.4 0 0 2 976 64.7
1993–
2002
76 19540 30.1 35 8502 13.4 47 9755 56.9
2003–
2011
29 6608 7.8 115 34762 12.8 27 5169 28.9whereas the decline in antigen prevalence appeared to
be slower (Figure 5).
Three studies in Table 4 are not plotted in Figures 4 or
5 since they did not have an annual or biannual MDA
schedule or consistent test used for evaluation:
1) The Milne Bay/Alotau district study by Sapak et al.
[44], which used diethylcarbamazine (DEC) salt for
six months and tested by Og4C3 antigen;
2) The Milne Bay/Samarai-Murua district/Lihir Island
studies, where baseline surveys before MDA were
done using Mf tests by Hii et al. [50] whereas follow-
ups after 2 and 4 MDAs were done with ICT tests
by MItja et al. [40].
3) The Southern Highlands/Nipa-Kutubu district study
of Prybylski et al. [3], which used a schedule of
weekly DEC for 6 months, and tested by Mf surveys.
Discussion
Survey results showed large variation in prevalence over
the country, which is in line with current research find-
ings and historical data dating back to 1912 [11]. Such
heterogeneity across the country is presumably relatedTable 3 Classification of districts by three criteria
schemes
1 GPELF
criteria
2 GPELF modified
criteria
3 Alternative
criteria
High endemic 60 36 34
Low endemic 25 15
Non endemic 20 20 31
Unknown 9 8 9
Total districts 89 89 89
Figure 3 (See legend on next page.)
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Figure 3 Maps showing classification of districts by endemicity, according to three criteria schemes. a. Map with districts classified using
GPELF criteria scheme 1. Red: endemic, >0% pos; Green: non-endemic, 0% pos; Black: unknown; results from all types of test. b. Map with districts
classified using modified GPELF criteria scheme 2. Red: High endemic, ≥5% pos; Yellow: Low endemic, >0% and <5% pos (or unknown but all
adjacent districts >0%); Green: non-endemic, 0% pos; Black: unknown; results from all types of test. c. Map with districts classified using alternative
criteria scheme 3. Red: high endemic; ≥5% pos; Yellow: low endemic, ≥1% and <5% pos; Green: non-endemic, <1% pos; Black: unknown; Mf
results used if available, otherwise ICT.
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http://www.parasitesandvectors.com/content/6/1/7to the diverse geography, altitude and ecology in this
unique country. The differences may also be explained
by the diversity of mosquito vectors found in different
regions and their ability to transmit. Anopheles vectors
have been shown to be more efficient in transmission
than Culex in Papua New Guinea [9], but there are
major gaps in the current knowledge of LF vectors and
intensity of transmission (except in one or two small
areas) as well as on the impact of vector-based interven-
tions. Variation in prevalence may be related to previous
malaria control activities, including past insecticide
spraying and more recently the distribution of mosquito
nets of all types, as well as to some extent, MDA for LF
in a limited number of sites.
The data presented and summarized in this study are
potentially not representative of the true situation in
Papua New Guinea because some survey sites were pur-
posively selected to identify LF where it was thought to
exist, and the results from the different surveys are not
weighted. Therefore the prevalence estimates should be
regarded as likely to be overestimates for the country as a
whole. Despite these limitations, the survey results show
generally lower prevalence of LF than is usually stated for
Papua New Guinea, which is encouraging for the LF pro-
gramme’s potential success. In addition, despite potential
biases in site selection and assays used over time, the
review suggests a clear decreasing trend in prevalence over
the three broad time periods (Table 2).
The highest prevalence estimates were consistently found
in the coastal provinces, especially those in the north and
west of the country, before the year 2000. This is as
expected given the warmer temperatures and higher hu-
midity in these low-lying areas favoring mosquito transmis-
sion. Some regions, including the highland provinces and
more developed areas near Port Moresby or around mine
sites, tend to have lower prevalence particularly since 2000,
and may be a reflection of the influence of urbanization
(which is more unfavourable to Anopheles vectors) and
climate as well as control measures.
The spatial heterogeneity of LF observed here in Papua
New Guinea is typical of the disease worldwide. There is
no doubt that similar records of past surveys exist in
other countries and regions, and the compilation and
mapping of such data in a systematic way including
details on tests used, persons sampled and up-to-datepopulation estimates would enable better prioritization
of MDA efforts. Such assessments would assist in moni-
toring progress and efficacy of the global LF elimination
programme and accelerate its achievements.
Many of the surveys included in this analytical review
were conducted as part of research, or before GPELF
mapping criteria were formulated. Therefore, it is diffi-
cult to apply the standard GPELF criteria or threshold
for endemicity (one or more positives per 250 persons
sampled) to such data. The GPELF modified criteria
scheme 2 included in this study aimed to stratify the
level of risk more finely than just non-endemic/endemic.
The third alternate criteria scheme was developed to
classify a district as negative if prevalence was less than
1% (rather than 0%), since many districts had sampled
more than the minimum number needed for Lot Quality
Assurance Sampling (LQAS) mapping, and to give more
weight to Mf rather than antigen surveys. This review
has identified nine districts that remain to be classified,
although one (in West Sepik) is likely endemic since it is
surrounded on all borders by endemic districts.
Previous estimates stated that five million people in
Papua New Guinea are at risk of LF [33] out of a total
population estimated to be between 6.3 and 6.8 million
[31,32]. Using the LF district classifications gathered here,
together with population estimates for 2010 by district
(generated from the 2000 census using the province-
specific growth rates from 1980–2000 [31]), we can quan-
tify the number of persons potentially at risk of LF in
Papua New Guinea who need MDA or other intervention
to interrupt LF transmission, as follows:
1. By GPELF criteria, 4.81 million people (70.4% of the population) live
in 60 ‘endemic’ districts;
 0.73 million (10.7%) live in the nine unknown
districts.2. By modified GPELF criteria, 2.94 million (43.1% of the population) live in 36
‘high endemic’ districts;
 1.94 million (28.3%) live in 25 ‘low endemic’
districts;
Table 4 Summary of pre and post MDA survey results
Province District Locality Test MDA
drug
Frequency
(if > =1 MDA)
Pre-MDA Post 1 MDA Post 2 MDA Post 3 MDA Post 4 MDA Post > =5 MDA Reference
Yr No
pers
%
pos
Yr No
pers
%
pos
Yr No
pers
%
pos
Yr No
pers
%
po
Yr No
pers
%
pos
Yr No
pers
%
pos
E Sepik Ambunti-
Dreikikir
4 mod
trans
villages
Mf DEC +
IVM
Annual 1994 797 47.2 1995 756 20.6 1996 790 5.7 1997 819 1.0 1998 750 0.9 [4]
E Sepik Ambunti-
Dreikikir
3 high
trans
villages
Mf DEC +
IVM
Annual 1994 281 76.9 1995 318 31.8 1996 311 23.8 1997 303 10 1998 266 5.3 [4]
E Sepik Ambunti-
Dreikikir
4 mod
trans
villages
Mf DEC Annual 1994 903 42.2 1995 815 29.2 1996 802 15.1 1997 692 6.8 1998 639 1.6 [4]
E Sepik Ambunti-
Dreikikir
3 high
trans
villages
Mf DEC Annual 1994 243 76.1 1995 192 51.0 1996 253 42.3 1997 257 21 1998 165 10.9 [4]
E Sepik Ambunti-
Dreikikir
7 villages Og4C3 DEC Annual 1994 177 83.6 1998 100 78 2003 531 16.9 [7]
Madang Sumkar Bagabag Is Mf DEC or
ALB +
DEC
1998 1026 28.5 2001 729 16.1 [43] [37]
Madang Usino-
Bundi
4 villages Mf ALB +
DEC
Annual 2003 571 18.6 2004 696 8.3 2005 714 3.4 2006 529 1.3 [39]
Madang Usino-
Bundi
4 villages ICT ALB +
DEC
Annual 2003 558 47.5 2004 692 35.1 2005 695 25.2 2006 543 17 [39]
Milne Bay Alotau Buhutu
valley
Og4C3 DEC Salt (for
6 months)
1995 434 55 1996 100 36.3 [44,45]
Milne Bay Alotau Dogura Og4C3 DEC 1995 255 71 1996 100 66 [44,45]
Milne Bay Samarai-
Murua
Basalaki Is Og4C3 ALB +
DEC
Annual 1998 100 74 2003 100 35 [46]
Milne Bay Samarai-
Murua
Misima Is Mf DEC +
IVM
Annual 1996 100 63.1 1997 100 2.8 [46]
Milne Bay Samarai-
Murua
Misima Is Og4C3 ALB +
DEC
Annual 1997 144 53 2003 484 0.2 [46]
New
Ireland
Namanatai Lihir Is / E
Coast
ICT ALB +
DEC
2003 3009 7.7 2008 3799 0.8 [40]
New
Ireland
Namanatai Lihir Is / W
Coast
ICT ALB +
DEC
2003 1969 30.7 2008 2464 7.5 [40]
S
Highlands
Nipa-
Kutubu
Mt Bosavi:
Fogomaiyu
Mf DEC Weekly (for 6
mths) + ITN
1987 79 92 1987 100 6 [3]
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Table 4 Summary of pre and post MDA survey results (Continued)
Western Middle Fly Lake
Murray:
Usukof
Og4C3 ALB or
ALB +
DEC
Bi-annual 1999 62 14.5 1999 168 6 2000 168 4.2 [47]
Western Middle Fly Lake
Murray:
Giakoret
Og4C3 ALB +
DEC
1999 67 77.6 2000 25 28 [47]
Western Middle Fly Nomad Og4C3 ALB +
DEC
1999 262 83.2 2000 146 80.1 [47]
Western North Fly Star Mtns
A + B
villages
Mf DEC Bi-annual (for
2 yrs) then
annual (for 2 yrs)
1986 286 34.4 1988 302 12 1990 503 6.4 [48]
Western North Fly Star Mtns
B villages
Mf DEC Annual 1988 312 45.14 1990 372 26.14 [48]
Western North Fly Rumginae
area
Mf DEC Annual 1991 1034 32 1992 208 13 1993 248 7 [49]
Mf: microfilariae; DEC: diethylcarbamazine; IVM: ivermectin; ALB: albendazole.
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Figure 4 Percentage of persons positive for Mf in sites surveyed more than once, according to number of rounds of MDA in that
location.
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Figure 5 Percentage of persons positive for LF antigenaemia in sites surveyed more than once, according to number of rounds of
MDA in that location.
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districts.3. By alternative criteria, 2.68 million (39.2% of the population) live in 34
‘high endemic’ districts;
 1.17 million (17.2%) live in 15 ‘low endemic’
districts;
 0.73 million (10.7%) live in the nine unknown
districts.Based on these different criteria schemes, we can rule out
from MDA at least 20 districts (1.29 million people), and
possibly as many as 40 districts (2.98 million people).
Twenty is the number of non-endemic districts as assessed
by the least specific GPELF Criteria Schemes 1 and 2, while
under the alternative criteria scheme 3, a total of 31
districts are classified as non-endemic plus potentially nine
more (those with currently unknown prevalence). Under
criteria scheme 3, the priority ‘high endemic’ districts for
MDA have a population of ‘only’ 2.68 million, compared to
4.81 million people in the endemic districts under criteria
scheme 1.
The classification of districts will guide the LF pro-
gramme towards the highest prevalence areas and leave
the lower or uncertain areas until last, to maximize impact
and avoid wasting resources in a country with significant
geographical challenges and limited transport infrastruc-
ture. The high endemic districts (numbering 36 and 34
under criteria schemes 2 and 3 respectively) should be the
most important focus, followed by the low endemic
districts (25 and 15 respectively). Prioritizing high endemic
districts will increase the LF programme’s ability to deliver
MDA, which as this collation of data clearly highlights has
a major impact on prevalence and transmission.
It should be noted that the information available for some
districts is limited (one survey site), and it is possible that
some may have been wrongly classified as non-endemic.
Further surveys in such districts may be warranted when
reports of LF morbidity, especially in young people, are
received from health workers. It is also important to
consider that many districts are large in geographical area
(e.g. in Western Province), and thus potentially have areas
within them that have different transmission intensity. All
districts comprise a number of smaller administrative units
called local level governments (LLGs). To date, some survey
sites have only been mapped to district, but once survey
points are all individually geo-located, it will be possible to
classify endemicity of LLGs in the same way as districts and
identify further subdistrict areas not needing MDA. The
survey point locations data can also be used to model risk
factors for infection (e.g. altitude, malaria risk, net coverage,
population density, proximity to water) in future.The MDA impact studies were undertaken in areas with
different levels of endemicity and different ecological set-
tings, which further supports the likelihood of successful
elimination in Papua New Guinea, especially if coupled
with vector control such as the recent scale up of LLIN
distribution across many districts. The fact that LF is
transmitted mainly by Anopheles vectors may be an ad-
vantage as this genus is more likely than Culex, Mansonia
or Aedes to be impacted with traditional insecticide-based
control methods such as ITNs, LLINS and IRS in an inte-
grated vector management strategy as is currently being
promoted by WHO [51]. A recent review has also advo-
cated integrated vector management for malaria and LF
control and highlighted the potential synergistic impact
on both diseases [19].
Above all, this review of data to date highlights the
gaps in data and our knowledge, such as the need to
classify the remaining nine unknown districts. The
greatest need is to mobilize a critical mass of in-country
support and resources from interested funding agencies
and international stakeholders with the aim to eliminate
LF in Papua New Guinea by 2020.
Conclusions
This analytical review of past surveys of LF in Papua New
Guinea has enabled the country to more accurately estimate
the national burden of LF, identify gaps in knowledge and
predict the impact of MDA and/or vector control. Overall,
national prevalence appears less than usually stated in the
literature, especially in surveys in more recent years.
Prioritization of districts by level of prevalence will
strengthen the control programme, eliminate MDA in
unnecessary areas and increase the likelihood of reaching
the target of interruption of transmission by 2020.
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